Antiplatelet Therapy in a Patient with Coronary Artery Disease and Myelodysplastic Syndrome with Thrombocytopenia

Francisco José Fernández-Fernández1, Eugenia Ameneiros-Lago1, Cintia Tuñas-Gesto2, Inmaculada Gómez-Buela1

ABSTRACT
To date, there are no sufficient data to make firm recommendations on the treatment of patients with severe thrombocytopenia who require antiplatelet therapy after experiencing acute coronary syndrome. Therefore, we think that it is important to communicate the experience with individual cases. We report the case of a patient who presented with pericardial effusion causing cardiac tamponade. He had thrombocytopenia associated with myelodysplastic syndrome, and ten weeks before this admission, percutaneous transluminal coronary angioplasty with implantation of drug-eluting stents was performed for non-ST-segment elevation acute coronary syndrome. Platelets in myelodysplastic syndromes are dysfunctional, which exacerbates bleeding from thrombocytopenia, and the management of atherosclerotic cardiovascular disease in these patients is challenging.

KEYWORDS
myelodysplastic syndromes; thrombocytopenia; acute coronary syndrome; antiplatelet therapy; clopidogrel; drug-eluting stents

AUTHOR AFFILIATIONS
1 Department of Internal Medicine, Complejo Hospitalario Universitario de Ferrol, Ferrol 15405, Spain
2 Section of Neurology, Complejo Hospitalario Universitario de Ferrol, Ferrol 15405, Spain
* Corresponding author: Department of Internal Medicine, Complejo Hospitalario Universitario de Ferrol, Ferrol 15405, Spain; e-mail: ffj.fernandez2@gmail.com

Received: 30 March 2017
Accepted: 23 May 2017
Published online: 5 October 2017

Acta Medica (Hradec Králové) 2017; 60(2): 82–84
https://doi.org/10.14712/18059694.2017.98
© 2017 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
INTRODUCTION

The safety of antiplatelet therapy in patients who have acute coronary syndrome and thrombocytopenia is unknown, and there are no randomized studies to make firm recommendations on treatment approaches in such patients. Likewise, in patients with thrombocytopenia, the risk of bleeding varies and may depend upon the underlying cause (1, 2). Platelets in myelodysplastic syndromes are dysfunctional (3) and, after leukemic transformation and infection, bleeding is the next most common cause of death (4–6). On the other hand, thrombocytopenia itself is not protective and acute coronary syndromes have been reported in patients who have thrombocytopenia that is associated with various disorders (7–9). In the setting of cancer and hematologic malignancies, some smaller sized retrospective studies have shown that aspirin may be beneficial in thrombocytopenic patients experiencing acute coronary syndromes (10, 11). Therefore, the management of atherosclerotic cardiovascular disease in patients who have myelodysplastic syndrome with thrombocytopenia is challenging.

We report the case of a 77-year-old man who presented with pericardial effusion causing cardiac tamponade. He had thrombocytopenia associated with myelodysplastic syndrome, and ten weeks before this admission, percutaneous transluminal coronary angioplasty with implantation of drug-eluting stents was performed for non-ST-segment elevation acute coronary syndrome.

CASE REPORT

A 77-year-old man was admitted to our Department because of a pericardial effusion causing cardiac tamponade. The patient was a former smoker with a history of hypertension, hyperlipidemia, type 2 diabetes, interstitial lung disease, colon diverticular disease, and adenomatous colonic polyps. Ten weeks before this admission, he had been hospitalized for a non-ST-segment elevation acute coronary syndrome. Coronary angiography showed a 90% stenosis of the left main trunk, 99% stenosis of the proximal anterior descending artery, 75% stenosis of the mid portion of the anterior descending artery and 75% stenosis of the posterior descending artery. Percutaneous transluminal coronary angioplasty was performed with implantation of drug-eluting stents. On initial testing, the patient had pancytopenia with leukocytes 3.23 × 10^9/l, hemoglobin 10.9 g/dl and platelets 58 × 10^9/l. The presence of platelet clumping was reported in a peripheral blood smear. Ferritin, vitamin B12 and serum folate were normal. A bone marrow study was not performed. The patient was prescribed ticagrelor and acetylsalicylic acid. Two months after discharge, the count of platelets ranged from 36 × 10^9/l to 60 × 10^9/l during this time period. At 12 months follow-up the patient remains well, and there were no further thrombotic complications or significant bleeding episodes, with a platelet count of 31 × 10^9/l to 60 × 10^9/l during this time period.

DISCUSSION

To date, there are no guidelines on the treatment of patients with thrombocytopenia who require antiplatelet therapy after experiencing acute coronary syndrome. Therefore, it is important to communicate the experience with individual cases. In patients with thrombocytopenia, the risk of bleeding varies and may depend upon the underlying cause (1, 2). Younger circulating platelets are larger and more hemostatically active. For example, patients with primary immune thrombocytopenia have younger circulating platelets and, consequently, less severe bleeding symptoms than patients with a similar degree of thrombocytopenia due to bone marrow failure, whose platelets tend to be older and hypoactive (1, 3). Platelets in myelodysplastic syndromes often express abnormally low levels of procoagulant cell surface markers or lack intracellular granules, which exacerbates bleeding from thrombocytopenia (4–6).

The patient had a history of iron-deficiency anemia due to gastrointestinal blood losses, and deletion 20q on cytogenetic analysis. Thrombocytopenia is the most frequent cytopenia in myelodysplastic syndrome patients presenting with deletion 20q on cytogenetic analysis and, in these cases, the dysplasia is often subtle (12). Both factors could decrease the suspicion of the hematologic process, and drug-eluting stents were implanted for the multivessel revascularization of the patient with complex coronary anatomy. With respect to the pericardial effusion, a sero-pus as autoimmune manifestation of myelodysplastic syndrome has rarely been reported (13, 14). In these cases, the pericardial effusion usually responds to treatment with corticosteroids and this origin was unlikely in our patient. Likewise,
the performed studies and evolution ruled out the possibility of pericardial effusion due to infiltration of blast cells.

In summary, our patient, with drug-eluting stents, had a high thrombotic and hemorrhagic risk. There was a delay in establishing the diagnosis of myelodysplastic syndrome, and after 10 weeks with dual antiplatelet therapy, clopidogrel alone was effective with a platelet count of $31 \times 10^9/l$ to $60 \times 10^9/l$.

REFERENCES